The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. [electronic resource]
Producer: 20061109Description: 5902-9 p. digitalISSN:- 1078-0432
- Animals
- Cell Division -- drug effects
- Disease Models, Animal
- Drug Synergism
- Drug Therapy, Combination
- Female
- Humans
- Mammary Neoplasms, Experimental -- drug therapy
- Mice
- Mice, Transgenic
- Nicotinic Acids -- therapeutic use
- Piperidines -- therapeutic use
- Receptors, Estrogen -- metabolism
- Selective Estrogen Receptor Modulators -- pharmacology
- Survival Rate
- Tetrahydronaphthalenes -- therapeutic use
- Thiophenes -- therapeutic use
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.